Skip to main content

Table 1 Characteristics of randomized participants

From: A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease

 

Placebo N = 7

Posiphen N = 12

P

Age, years

74.6 ± 8.7

69.5 ± 7.6

0.19

Sex (Female: Male)

3 : 4

6 : 6

1.0

Education, years

14.9 ± 2.3

16 ± 3.4

0.45

MMSE

24 ± 4.4

24.5 ± 2.7

0.76

Concomitant medications

   

AChE-I

4 (57%)

6 (50%)

0.90

Memantine

3 (43%)

2 (16%)

0.21

Antidepressants

2 (28%)

9 (75%)

0.048

  1. AChE-I = acetylcholinesterase inhibitors. Specific antidepressants and treatment groups are as follows (some participants were taking more than one medication): citalopram (or escitalopram): 6 Posiphen; fluoxetine 1 placebo; sertraline 3 Posiphen; bupropion 1 placebo, 2 Posiphen; mirtazapine 1 Posiphen
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193